Skip to content

Expanded Access Policy

Our purpose at Actio Biosciences, Inc. is to develop new therapies that have a positive impact on patient health, and to serve patients, patient families and patient communities through education, empathy, and awareness.

We are united by a shared commitment to advancing science with purpose, aiming to turn new insights into therapies that can genuinely improve patients’ lives. We move with both urgency and care, recognizing the responsibility we carry to deliver progress. Every step forward matters, especially as patients continue to wait for safer, more effective treatment options.

Actio Biosciences is committed to making investigational drug ABS-1230 available to seriously ill patients with a life-threatening condition who will not be eligible for our clinical trials and do not have options for alternative therapies. In these unique circumstances, Actio Biosciences may consider expanded access requests, also known as compassionate use or managed access, from a treating healthcare provider (HCP) for an individual patient. Requests will be considered on a case-by-case basis. For a request to be considered, both the patient eligibility criteria and HCP responsibilities described below must be met. All requests must be submitted by the patient’s treating HCP and cannot be accepted from patients or family members.

Criteria Evaluated by Actio Biosciences

Actio Biosciences will evaluate whether:

Responsibilities of the Treating Healthcare Provider

The treating healthcare provider must: 

Actio Biosciences continually evaluates the benefit-risk profile of each of our investigational drugs as new clinical data becomes available. Because each patient’s circumstances are unique, the availability of ABS-1230 for one patient does not guarantee the availability for another patient whose circumstances and medical histories may be different.

Actio Biosciences is committed to evaluating all requests in a fair and equitable manner. We may require more detailed information in order to fully evaluate a request. Each request will be given careful consideration by Actio Biosciences whose decisions are final.

Expanded Access Policy dated:  October 19, 2026

Actio is now part of Jazz Pharmaceuticals

Select Jazz for more information about Jazz Pharmaceuticals.

Select continue to proceed to the Actio website.

Jazz